CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-02 | Meisner Lara Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,875 | 18,128 | ||
| 2023-04-12 | Myers Scott Dunseth Chief Executive Officer | Purchase | +4,000 | $25.37 | $101K | 259,500 |
| 2023-03-13 | Myers Scott Dunseth Chief Executive Officer | Purchase | +5,500 | $29.15 | $160K | 255,500 |
| 2023-03-09 | Meisner Lara General Counsel and Secretary | Sale | −29,971 | $29.07 | $871K | 0 |
| 2023-02-08 | Katz Barrett Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +108,000 | 108,000 | ||
| 2023-02-08 | Melvin Carrie COO | Grant or award · Stock Option (Right to Buy) | +54,000 | 54,000 | ||
| 2023-02-08 | Humer Kristian CFO and CBO | Grant or award · Stock Option (Right to Buy) | +108,000 | 108,000 | ||
| 2023-02-08 | Meisner Lara General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +108,000 | 108,000 | ||
| 2023-02-06 | Myers Scott Dunseth Chief Executive Officer | Grant or award | +250,000 | 250,000 | ||
| 2023-02-06 | Myers Scott Dunseth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,000,000 | 1,000,000 | ||
| 2023-02-02 | Violin Jonathan Chief Executive Officer | Option exercise | +50,000 | $0.15 | $8K | 530,905 |
| 2023-02-02 | Violin Jonathan Chief Executive Officer | Sale | −50,000 | $36.80 | $1.8M | 480,905 |
| 2023-02-02 | Violin Jonathan Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −50,000 | 239,205 | ||
| 2023-02-02 | Violin Jonathan Chief Executive Officer | Sale | −50,000 | $36.80 | $1.8M | 430,905 |
| 2023-01-23 | Meisner Lara General Counsel and Secretary | Option exercise | +4,971 | $23.03 | $114K | 4,971 |
| 2023-01-23 | Meisner Lara General Counsel and Secretary | Option exercise | +1,872 | $14.00 | $26K | 6,843 |
| 2023-01-23 | Meisner Lara General Counsel and Secretary | Sale | −6,843 | $35.66 | $244K | 0 |
| 2023-01-23 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −4,971 | 39,750 | ||
| 2023-01-23 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −1,872 | 20,003 | ||
| 2023-01-17 | Katz Barrett Chief Medical Officer | Option exercise | +24,853 | $23.03 | $572K | 24,853 |
Page 6 of 10 · 182 trades